GO:0035772 interleukin-13-mediated signaling pathway: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0035772 describes the molecular signaling cascade triggered when interleukin-13 (IL-13) binds its receptor on the cell surface, culminating in regulation of downstream cellular processes such as transcription.
• IL-13 signaling critically involves the insulin receptor substrate-1-related 4PS substrate, but not the interleukin-2 receptor gamma chain, as shown in early biochemical studies.
• IL-13 signaling upregulates IL-13Rα2 in pulmonary fibroblasts in a CXCR3-dependent manner, linking this pathway to fibrosis and tissue remodeling.
• The pathway drives Paneth cell degranulation and antimicrobial peptide release, highlighting its role in innate immunity.
• In rheumatoid arthritis, dendritic cells from patients show defective IL-13-mediated increase of Fc gamma RII expression, indicating disease-associated dysregulation.
• IL-13 signaling can restrict diesel exhaust particle-induced proliferation of lung epithelial A549 cells, with implications for tissue remodeling and fibrosis.
Description
The interleukin-13-mediated signaling pathway (GO:0035772) is a biological process defined as the series of molecular signals initiated by interleukin-13 binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription. Interleukin-13 (IL-13) is a pleiotropic cytokine that orchestrates diverse cellular responses, from immune regulation to tissue remodeling, and its signaling cascade is a focal point for understanding inflammatory and fibrotic diseases. Researchers study this pathway to dissect how a single cytokine can trigger context-dependent outcomes, such as fibroblast activation, epithelial cell proliferation, and antimicrobial defense. The pathway's core components include the IL-13 receptor complex and downstream adaptor molecules like the 4PS substrate, which was identified as a key transducer in IL-13 signaling. Dysregulation of this pathway is implicated in conditions ranging from rheumatoid arthritis to pulmonary fibrosis, making it a high-value target for therapeutic intervention and CRISPR-based functional genomics.
interleukin-13-mediated signaling pathway At A Glance
| GO ID | GO:0035772 |
|---|---|
| GO term | interleukin-13-mediated signaling pathway |
| Ontology | biological_process |
| Synonym | IL-13-mediated signaling pathway; interleukin-13-mediated signalling pathway |
| Major function | Transduces interleukin-13 signals from the cell surface to regulate downstream cellular processes, including transcription. |
| Key transducer | Insulin receptor substrate-1-related 4PS substrate (but not IL-2R gamma chain). |
| Tissue contexts | Pulmonary fibroblasts, Paneth cells, lung epithelial cells, dendritic cells. |
| Disease relevance | Pulmonary fibrosis, rheumatoid arthritis, tissue remodeling. |
What Is GO:0035772?
In our own words, GO:0035772 encompasses the entire sequence of molecular events that begins when interleukin-13 (IL-13) binds to its receptor on the surface of a target cell. This binding event triggers intracellular signaling cascades that ultimately regulate downstream cellular processes, including changes in gene transcription. The pathway is synonymous with IL-13-mediated signaling pathway and interleukin-13-mediated signalling pathway. It is a biological process that integrates extracellular cytokine cues with intracellular responses, involving receptor activation, adaptor protein recruitment, and transcriptional regulation.
Why Is interleukin-13-mediated signaling pathway Important in Cell Biology?
The interleukin-13-mediated signaling pathway is critically important because it serves as a central node linking cytokine signals to diverse physiological and pathological outcomes. It regulates immune cell function, epithelial cell behavior, and tissue remodeling, and its dysregulation is associated with chronic inflammatory diseases such as rheumatoid arthritis and fibrosis. Understanding this pathway at the molecular level enables researchers to identify therapeutic targets and develop precision interventions, particularly through CRISPR-based gene editing approaches that can dissect causal gene contributions.
• IL-13 signaling drives upregulation of IL-13Rα2 in pulmonary fibroblasts via a CXCR3-dependent mechanism, directly linking the pathway to fibrosis.
• The pathway stimulates Paneth cell degranulation and antimicrobial peptide release, underscoring its role in innate immune defense.
• IL-13-mediated mechanisms restrict diesel exhaust particle-induced proliferation of lung epithelial A549 cells, with implications for tissue remodeling and fibrosis.
• The 4PS substrate, but not the interleukin-2R gamma chain, is involved in IL-13-mediated signal transduction, defining a unique signaling axis.
• Dendritic cells from rheumatoid arthritis patients lack the IL-13-mediated increase of Fc gamma RII expression, revealing disease-associated functional consequences.
• The pathway is a target for understanding how cytokines modulate transcription and cellular processes in inflammatory microenvironments.
• IL-13 signaling intersects with chemokine receptor pathways (e.g., CXCR3), highlighting cross-talk in fibrotic diseases.
• Studying this pathway aids in identifying biomarkers and therapeutic targets for asthma, fibrosis, and autoimmune conditions.
• CRISPR screens can uncover novel regulators of IL-13 signaling, accelerating drug discovery.
• The pathway's context-dependent effects make it a model for dissecting signaling specificity in different cell types.
What Happens During interleukin-13-mediated signaling pathway?
Interleukin-13 Binding and Receptor Activation
In simple terms: IL-13 docks onto its receptor on the cell surface, like a key fitting a lock, to start the signal.
The pathway begins when interleukin-13 (IL-13) binds to its receptor complex on the surface of a target cell. This binding event initiates a series of molecular signals that propagate into the cell. The receptor activation is the first committed step, and it determines the specificity of downstream responses. Early studies identified that the insulin receptor substrate-1-related 4PS substrate, but not the interleukin-2R gamma chain, is involved in IL-13-mediated signal transduction, distinguishing it from related cytokine pathways.
Intracellular Signal Transduction via 4PS Substrate
In simple terms: Inside the cell, a protein called 4PS acts as a messenger to carry the signal forward.
Following receptor engagement, intracellular signaling molecules are recruited. The 4PS substrate, an insulin receptor substrate-1-related protein, plays a key role in transducing the IL-13 signal. This step is critical for relaying the signal from the receptor to downstream effectors. The involvement of 4PS but not the interleukin-2R gamma chain highlights a distinct signaling mechanism for IL-13 compared to other cytokines.
Regulation of Downstream Cellular Processes
In simple terms: The signal reaches the nucleus and changes which genes are turned on or off.
The ultimate outcome of the pathway is the regulation of downstream cellular processes, including transcription. For example, IL-13 signaling upregulates IL-13Rα2 in pulmonary fibroblasts in a CXCR3-dependent manner, demonstrating transcriptional regulation. In Paneth cells, IL-13 signaling triggers degranulation and antimicrobial peptide release, a cellular process distinct from transcription. In lung epithelial A549 cells, IL-13-mediated mechanisms restrict diesel exhaust particle-induced cell proliferation, linking the pathway to cell cycle regulation.
Context-Dependent Outcomes in Different Cell Types
In simple terms: The same signal can cause different effects depending on the cell type.
The interleukin-13-mediated signaling pathway exhibits context-dependent outcomes. In pulmonary fibroblasts, it upregulates IL-13Rα2. In Paneth cells, it induces degranulation. In lung epithelial cells, it restricts proliferation. In dendritic cells from rheumatoid arthritis patients, it fails to increase Fc gamma RII expression, indicating disease-specific dysregulation. These examples illustrate the pleiotropic nature of IL-13 signaling and the importance of cellular context.
Key Genes Involved in GO:0035772 interleukin-13-mediated signaling pathway
The following genes and proteins are central to the interleukin-13-mediated signaling pathway, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IL13 | Ligand that initiates the pathway by binding to its receptor | Target for modulating pathway activation in inflammatory diseases |
| IL13RA1 | Receptor subunit that binds IL-13 | Key component for signal initiation; knockout studies can abolish pathway |
| IL13RA2 | Decoy receptor upregulated by IL-13 signaling | Feedback regulator and biomarker in fibrosis |
| IL4R | Receptor subunit shared with IL-4 | Determines signaling specificity and cross-talk |
| IRS1 | Insulin receptor substrate-1-related 4PS substrate involved in signal transduction | Critical transducer; knockdown blocks IL-13 signaling |
| CXCR3 | Chemokine receptor required for IL-13-mediated upregulation of IL-13Rα2 | Modulates pathway output in pulmonary fibroblasts |
| FCGR2 | Fc gamma RII, whose expression is increased by IL-13 in dendritic cells | Marker of functional IL-13 response; defective in rheumatoid arthritis |
| STAT6 | Transcription factor commonly activated downstream of IL-13 | Mediates transcriptional regulation; not directly cited but inferred from pathway definition |
| JAK1 | Janus kinase associated with IL-13 receptor | Phosphorylates STAT6; potential drug target |
| JAK3 | Janus kinase family member | May participate in IL-13 signaling in some contexts |
| TYK2 | Tyrosine kinase 2 | Potential mediator of IL-13 signaling |
| SOCS1 | Suppressor of cytokine signaling | Negative regulator of IL-13 pathway |
| SOCS3 | Suppressor of cytokine signaling | Feedback inhibitor of IL-13 signaling |
| PIAS1 | Protein inhibitor of activated STAT | Modulates STAT6 activity |
| NFKB1 | Nuclear factor kappa B subunit 1 | Inflammatory transcription factor cross-talk |
| MAPK1 | Mitogen-activated protein kinase 1 | Downstream signaling node |
| AKT1 | AKT serine/threonine kinase 1 | Survival and proliferation signaling |
| MTOR | Mechanistic target of rapamycin | Integration of IL-13 signals with metabolism |
How Is interleukin-13-mediated signaling pathway Regulated?
The interleukin-13-mediated signaling pathway is regulated at multiple levels. Negative feedback is provided by suppressors of cytokine signaling (SOCS) proteins, which can inhibit JAK-STAT activation. The decoy receptor IL13RA2 is upregulated by IL-13 signaling itself, serving as a feedback inhibitor. Additionally, CXCR3 is required for IL-13-mediated upregulation of IL-13Rα2 in pulmonary fibroblasts, indicating cross-regulation by chemokine receptors. In rheumatoid arthritis, dendritic cells lack the IL-13-mediated increase of Fc gamma RII expression, suggesting disease-associated defects in pathway regulation. These regulatory mechanisms ensure context-dependent and transient signaling.
interleukin-13-mediated signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IL13 | Pulmonary fibrosis, asthma | IL13 knockout mouse or overexpression in lung fibroblasts |
| IL13RA2 | Fibrosis, tissue remodeling | IL13RA2 knock-in reporter in pulmonary fibroblasts |
| CXCR3 | Fibrotic diseases | CXCR3 knockout in fibroblast cell lines |
| FCGR2 | Rheumatoid arthritis | FCGR2 point mutation in dendritic cells |
| IL13 | Antimicrobial defense | Paneth cell-specific IL13 overexpression |
Pulmonary Fibrosis and Tissue Remodeling
IL-13-mediated signaling is critically involved in pulmonary fibrosis. In pulmonary fibroblasts, IL-13 upregulates IL-13Rα2 in a CXCR3-dependent manner, promoting fibrotic responses. Additionally, IL-13-mediated mechanisms restrict diesel exhaust particle-induced proliferation of lung epithelial A549 cells, with implications for tissue remodeling and fibrosis. These findings suggest that targeting this pathway could mitigate fibrotic progression.
Rheumatoid Arthritis
Dendritic cells from patients with rheumatoid arthritis lack the interleukin-13-mediated increase of Fc gamma RII expression, which has clear functional consequences. This defect indicates that impaired IL-13 signaling contributes to the pathogenesis of rheumatoid arthritis, potentially affecting immune complex clearance and inflammation.
Innate Immunity and Antimicrobial Defense
IL-13-mediated signaling triggers Paneth cell degranulation and antimicrobial peptide release, highlighting its role in innate immunity. Dysregulation of this process could compromise mucosal defense and contribute to inflammatory bowel diseases.
From interleukin-13-mediated signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does IL13 knockout abolish IL-13-mediated signaling? | IL13 knockout cell line (e.g., A549) |
| What is the role of 4PS substrate in signal transduction? | IRS1 point mutation or knockout |
| How does CXCR3 modulate IL-13Rα2 upregulation? | CXCR3 knockout pulmonary fibroblasts |
| Can IL-13 signaling be tracked in real time? | IL13RA2 tagged knock-in reporter |
| Does overexpression of IL-13 drive fibrosis? | IL13 overexpression in lung epithelial cells |
| What is the effect of defective Fc gamma RII expression? | FCGR2 knock-in in rheumatoid arthritis dendritic cells |
How to Study the interleukin-13-mediated signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Transcriptional changes | Identify IL-13 target genes |
| Proteomics | Protein interactions and modifications | Discover signaling complexes |
| Degranulation assay | Antimicrobial peptide release | Paneth cell function |
| Proliferation assay | Cell growth | Lung epithelial response |
| Western blot | Protein expression and phosphorylation | Validate signaling activation |
| Immunofluorescence | Protein localization | Track IL-13Rα2 upregulation |
| CRISPR screen | Gene essentiality | Identify novel regulators |
| Flow cytometry | Fc gamma RII expression | Dendritic cell function |
Transcriptional Profiling (RNA-seq)
RNA sequencing can measure changes in gene expression downstream of IL-13 signaling, such as upregulation of IL13RA2 or FCGR2. This method is ideal for identifying transcriptional targets and pathway signatures in different cell types.
Proteomic Analysis
Mass spectrometry-based proteomics can identify proteins involved in IL-13 signal transduction, such as the 4PS substrate and its interaction partners. This approach reveals post-translational modifications and signaling complexes.
Functional Assays for Degranulation
Paneth cell degranulation and antimicrobial peptide release can be quantified using secretion assays and antimicrobial activity tests. These methods directly measure a cellular outcome of IL-13 signaling.
Cell Proliferation Assays
Proliferation of lung epithelial cells in response to diesel exhaust particles and IL-13 can be assessed using MTT or BrdU assays. This measures the pathway's impact on cell cycle regulation.
How CRISPR Can Be Used to Study GO:0035772 interleukin-13-mediated signaling pathway
Knockout
CRISPR knockout of IL13, IL13RA1, or IRS1 can abolish IL-13-mediated signaling, enabling researchers to test the requirement of specific genes for pathway activation. For example, knocking out CXCR3 in pulmonary fibroblasts can determine its role in IL-13-mediated upregulation of IL-13Rα2.
Point Mutation
Introducing point mutations in signaling components, such as the 4PS substrate, can dissect domain-specific functions and phosphorylation sites critical for IL-13 signal transduction. This approach is valuable for understanding structure-function relationships.
Knock-in
Knock-in of tagged IL13RA2 or FCGR2 allows real-time tracking of pathway activity and protein localization. For instance, a fluorescent tag on IL-13Rα2 can monitor its upregulation in live cells.
Overexpression
Overexpression of IL13 or constitutively active signaling intermediates can drive pathway activation in the absence of ligand, modeling disease states such as fibrosis. This is useful for gain-of-function studies.
How EDITGENE Supports interleukin-13-mediated signaling pathway Research
Researchers studying interleukin-13-mediated signaling pathway-related genes often need to determine whether a candidate gene is causally involved in pathway activation, regulation, or downstream effects. EDITGENE provides a comprehensive suite of CRISPR-based services to enable such functional studies with precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for interleukin-13-mediated signaling pathway research.
Frequently Asked Questions About interleukin-13-mediated signaling pathway
What is the interleukin-13-mediated signaling pathway?
It is the series of molecular signals initiated by interleukin-13 binding to its receptor on the cell surface, ending with regulation of a downstream cellular process such as transcription.
What genes are involved in the interleukin-13-mediated signaling pathway?
Key genes include IL13, IL13RA1, IL13RA2, IL4R, IRS1, CXCR3, and FCGR2, among others.
What is the role of the 4PS substrate in IL-13 signaling?
The insulin receptor substrate-1-related 4PS substrate, but not the interleukin-2R gamma chain, is involved in IL-13-mediated signal transduction.
How does IL-13 signaling contribute to pulmonary fibrosis?
IL-13 upregulates IL-13Rα2 in pulmonary fibroblasts via a CXCR3-dependent mechanism, promoting fibrotic responses.
What is the connection between IL-13 signaling and rheumatoid arthritis?
Dendritic cells from rheumatoid arthritis patients lack the IL-13-mediated increase of Fc gamma RII expression, indicating defective signaling.
Can IL-13 signaling induce antimicrobial peptide release?
Yes, IL-13-mediated signaling triggers Paneth cell degranulation and antimicrobial peptide release.
How does IL-13 affect lung epithelial cell proliferation?
IL-13-mediated mechanisms restrict diesel exhaust particle-induced proliferation of lung epithelial A549 cells.
What methods are used to study IL-13 signaling?
Common methods include RNA-seq, proteomics, degranulation assays, proliferation assays, and CRISPR screens.
What are the synonyms for GO:0035772?
The synonyms are IL-13-mediated signaling pathway and interleukin-13-mediated signalling pathway.
How can CRISPR help study the interleukin-13-mediated signaling pathway?
CRISPR knockout, point mutation, knock-in, and overexpression models can dissect gene function and identify therapeutic targets.
Conclusion
The interleukin-13-mediated signaling pathway (GO:0035772) is a fundamental biological process that translates extracellular IL-13 cues into diverse cellular responses, from transcriptional regulation to degranulation and proliferation. Its dysregulation is linked to fibrosis, rheumatoid arthritis, and impaired innate immunity. Understanding the molecular players, such as the 4PS substrate and CXCR3, provides opportunities for therapeutic intervention. CRISPR-based functional genomics, supported by EDITGENE's services, offers a powerful approach to uncover novel regulators and validate drug targets in this pathway.
References
- 1. Barnes JC et al.. 2015. CXCR3 Requirement for the Interleukin-13-Mediated Up-Regulation of Interleukin-13Rα2 in Pulmonary Fibroblasts.. Am J Respir Cell Mol Biol 53(2):217-25 PMID: 25514189
- 2. Stockinger S et al.. 2014. Interleukin-13-mediated paneth cell degranulation and antimicrobial peptide release.. J Innate Immun 6(4):530-41 PMID: 24556597
- 3. Niranjan R et al.. 2022. Eosinophils Restrict Diesel Exhaust Particles-induced Cell Proliferation of Lung Epithelial A549 Cells via Interleukin-13 Mediated Mechanisms: Implications for Tissue Remodeling and Fibrosis.. Comb Chem High Throughput Screen 25(10):1682-1694 PMID: 34986769
- 4. Wang LM et al.. 1995. The insulin receptor substrate-1-related 4PS substrate but not the interleukin-2R gamma chain is involved in interleukin-13-mediated signal transduction.. Blood 86(11):4218-27 PMID: 7492780
- 5. Radstake TR et al.. 2005. Dendritic cells from patients with rheumatoid arthritis lack the interleukin 13 mediated increase of Fc gamma RII expression, which has clear functional consequences.. Ann Rheum Dis 64(12):1737-43 PMID: 15878907
